Clinical efficacy and safety of gastric bypass stents for weight loss in obesity

YU Jia-hui; LIU Yan-jun

doi:10.19538/j.nk2025040106

Abstract：Objective To evaluate the therapeutic effects of gastric bypass stents on obesity and its related metabolic parameters as well as assess their clinical safety profile.Methods This retrospective analysis included 26 patients with obesity who underwent gastric bypass stent placement at Chengdu Third People's Hospital between August 2024 and March 2025.Stents were removed endoscopically at 12 weeks.Primary outcomes included total weight loss rate,changes in blood pressure,glucose,lipids,transaminases,uric acid,and safety endpoints.Results Among 26 patients,1 stent was prematurely removed due to persistent abdominal pain,and 1 was withdrawn for personal reasons.The remaining 24 patients[mean age(35.04±8.89)year;7 males,17 females]demonstrated significant improvements.At 12 weeks,the total weight loss rate was(8.95±5.59)％.Abdominal circumference was decreased from(104.21±7.62)cm to(98.57±7.38)cm.Visceral fat area was reduced from(173.99±21.06)cm2 to(153.21±30.34)cm2.Body fat percentage was lowered from(41.68±4.33)％to(39.49±5.95)％.Controlled attenuation parameter(CAP)score was declined from(313.09±52.68)dB/m to(256.00±26.81)dB/m.HOMA-IR was improved from 4.44(2.76,6.95)to 2.89(1.61,4.48).At 12 weeks,triglyceride levels decreased from 1.64(1.18,2.19)mmol/L to 1.31(1.06,1.58)mmol/L.Serum uric acid was decreased from(408.15±95.35)μmol/L to 354.25±76.13 μmol/L.Statistical significance was observed across all parameters(P＜0.05).Non-significant trends were observed for total cholesterol,High-density lipoprotein cholesterol(HDL-c),low-density lipoprotein cholesterol(LDL-c),homocysteine,muscle mass,and liver stiffness measurement(LSM)values.One severe adverse event occurred due to intolerance to gastrointestinal adverse effects.No cases of gastrointestinal bleeding/perforation,acute cholecystitis,pancreatitis,liver abscess,or stent migration were reported.Conclusion Gastric bypass stents achieve significant short-term weight loss and improvement in obesity-related metabolic parameters.The procedure demonstrates a clinically acceptable safety profile with minimal severe adverse events.